Sodium Restriction and Mineralocorticoid Receptor Antagonists
In a normotensive patient with proteinuria who cannot take ACE inhibitors or ARBs, the best medication option is a non-steroidal mineralocorticoid receptor antagonist (ns-MRA) such as finerenone, combined with aggressive dietary sodium restriction to <2.0 g/day.
Primary Recommendation: Finerenone (ns-MRA)
The KDIGO 2021 guidelines explicitly recommend ns-MRAs for patients with proteinuria despite standard therapy 1. While the guidelines primarily discuss this in the context of patients already on RAS inhibition, the 2022 ADA/KDIGO consensus specifically states that finerenone has proven kidney and cardiovascular benefits for patients with eGFR ≥25 mL/min/1.73 m², normal serum potassium, and albuminuria (ACR ≥30 mg/g) 2.
Dosing Algorithm for Finerenone:
- Start at 20 mg daily if eGFR >60 mL/min/1.73 m²
- Start at 10 mg daily if eGFR 25-60 mL/min/1.73 m²
- Baseline potassium must be ≤4.8 mmol/L (or ≤5.0 mmol/L per FDA label)
- Check potassium at 4 weeks after initiation and regularly thereafter
- Uptitrate to 20 mg if potassium remains <4.8 mmol/L
- Hold if potassium >5.5 mmol/L; restart at 10 mg when potassium ≤5.0 mmol/L 2
Essential Adjunctive Therapy: Sodium Restriction
Dietary sodium restriction to <2.0 g/day (<90 mmol/day) is critical and acts synergistically with any pharmacologic intervention 1. The KDIGO guidelines emphasize intensifying sodium restriction in patients who fail to achieve proteinuria reductions on medical therapy 1.
Additional Lifestyle Modifications:
- Weight normalization
- Smoking cessation
- Regular exercise 1
Alternative Consideration: Statins
Atorvastatin may provide modest antiproteinuric effects beyond lipid lowering. A 2003 controlled study demonstrated that atorvastatin added to ACE inhibitor/ARB therapy reduced proteinuria from 2.2 to 1.2 g/24 hours over one year, compared to minimal reduction without statin therapy 3. While this study included patients on RAS inhibition, the mechanism appears independent and could theoretically work in normotensive patients without ACE/ARB therapy, particularly if hyperlipidemia is present.
Important Caveats
Why Not Standard Diuretics Alone?
The KDIGO guidelines discuss diuretics extensively for edema management in nephrotic syndrome, not specifically for proteinuria reduction 1. Spironolactone (a steroidal MRA) is mentioned for refractory cases but carries higher hyperkalemia risk than finerenone, especially without the potassium-wasting effect of loop/thiazide diuretics that would be inappropriate in a normotensive patient 1.
The ACE/ARB Dilemma in Normotensive Patients
KDIGO acknowledges that evidence for ACE/ARB in normotensive patients with proteinuria is less strong 2. The guidelines note it "may be reasonable to delay initiation of ACEi or ARB for patients without hypertension" with certain podocytopathies expected to respond to immunosuppression 1. This creates the clinical space where your patient exists—proteinuria without hypertension and contraindication to RAS inhibition.
What Doesn't Work
Pentoxifylline showed no significant benefit when added to maximal ACE/ARB therapy in a 2007 study 4, suggesting limited utility as monotherapy for proteinuria reduction.
Monitoring Strategy
For finerenone therapy:
- Potassium and kidney function at 4 weeks, then regularly
- Watch for hyperkalemia (most common adverse effect)
- Monitor proteinuria reduction as treatment goal
- Continue therapy even if eGFR declines to <25 mL/min/1.73 m² as long as potassium remains acceptable 2
The combination of finerenone with aggressive sodium restriction represents the most evidence-based approach for reducing proteinuria in your normotensive patient who cannot take ACE inhibitors or ARBs, with the added benefit of proven cardiovascular and kidney outcomes.